MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.dld.2026.09.026

Медицинская библиотека · Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2026

A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemotherapy in pancreatic cancer.

Mori Martina, Fois Marco, Vincenzi Monica Maria, Tummineri Roberta, Giannini Laura, Palazzo Gabriele, Parma Gaia, Torrisi Miriam, Spezi Emiliano, Bezzi Carolina, Carconi Catia, Liscia Nicole, Macchini Marina, Mapelli Paola, Orsi Giulia, Picchio Maria, Vecchio Antonella Del, Chiti Arturo, Reni Michele, Passoni Paolo, Fiorino Claudio, Muzio Nadia Gisella Di

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The radiomic feature Statistical Percentile 10% (p10%), extracted from [¹⁸F]FDG-PET images, has been previously identified and validated as a robust predictor of distant progression-free survival (DPFS) in unresectable pancreatic cancer (LAPC). This study aimed to maximize its prognostic potential by combining p10% with CA19.9 serum levels and assessing its generalizability across distinct clinical settings.

METHODS

We analyzed 287 LAPC patients treated with chemoradiotherapy (CRT) and a validation cohort of 72 patients enrolled in the CASSANDRA trial (resectable/borderline-resectable PDAC). Cox models combined p10% with CA19.9 levels measured before RT in LAPC patients, and before surgery for CASSANDRA patients.

RESULTS

p10% was independently prognostic in both cohorts and its integration with CA19.9 significantly improved the prediction. In the LAPC cohort, the combined model achieved C-index=0.71, with median DPFS of 4.0-vs-15.0 months (p<0.0001;HR=3.22). In the pre-surgery setting (CASSANDRA trial), the model showed good rank-order discrimination (C-index=0.65), with median survival of 11.6 months vs not-reached (p=0.0018). However, the calibration slope of 0.54 suggests that absolute risk prediction requires recalibration in the surgical cohort.

CONCLUSIONS

Integrating p10% with CA19.9 provides a broader representation of tumor aggressiveness. The combined biomarkers demonstrate consistent performance across different disease stages supporting their use for treatment personalization.

Для цитирования: Mori Martina, Fois Marco, Vincenzi Monica Maria, Tummineri Roberta, Giannini Laura, Palazzo Gabriele, Parma Gaia, Torrisi Miriam, Spezi Emiliano, Bezzi Carolina, Carconi Catia, Liscia Nicole, Macchini Marina, Mapelli Paola, Orsi Giulia, Picchio Maria, Vecchio Antonella Del, Chiti Arturo, Reni Michele, Passoni Paolo, Fiorino Claudio, Muzio Nadia Gisella Di. A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemotherapy in pancreatic cancer.. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2026. DOI: 10.1016/j.dld.2026.09.026.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.